featured
Ten Practice Changes That I Will Make After Attending ASCO 2018
- Written by
-
Jeffrey
J.
Kirshner
MD, FACP, FASCO
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sparano JA, Gray RJ, Wood WC, et al TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA1.
- Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211). Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 4004.
- Earl HM, Hiller L, Vallier A-L, et al. PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 506.
- Hong YS, Kim SY, Lee JS, et al. Long-term results of the ADORE trial: Adjuvant oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) versus 5-fluorouracil and leucovorin (FL) after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 3501.
- Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 500.
- Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 501.
- Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA3503.
- Mejean A, Escudier B, Thezenas S, et al. CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA3.
- Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA9000.
- Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 9001.
- Lopes G, Wu Y-L, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA4.
- Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 502.
- Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract 503.
- Conroy T, Hammel P, Hebbar M, et al Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Paper presented at: American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2018; Chicago, IL. Abstract LBA4001.
Disclosure statements are available on the authors' profiles:
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.